Transdermal drug pharmacokinetics in man: Interindividual variability and partial prediction

被引:42
作者
Farahmand, Sara [1 ]
Maibach, Howard I. [1 ]
机构
[1] Univ Calif San Francisco, Dept Dermatol, Sch Med, San Francisco, CA 94143 USA
关键词
Transdermal drug delivery; Pharmacokinetics; Interindividual variation; QSPR; Skin absorption; Transdermal patch; CONTRACEPTIVE PATCH; IN-VITRO; NICOTINE PHARMACOKINETICS; PERCUTANEOUS-ABSORPTION; DELIVERY SYSTEMS; HYPOGONADAL MEN; MENOREST(R) 50; SKIN; ESTRADIOL; PHARMACODYNAMICS;
D O I
10.1016/j.ijpharm.2008.11.020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A database of human dermatopharmacokinetic parameters of 12 transdermal patches is established. The effect of system design, application site, and metabolism on pharmacokinetic data is discussed, and interindividual variability of data and its possible sources evaluated. Using multiple regression analysis, two equations based on drugs physicochemical characteristics are suggested for partial prediction of peak plasma concentration (C-max) after patch application. Patch application presumably decreases variance as rub-off, wash and exfoliation steps are diminished. The results showed that interindividual variation, in terms of coefficient of variation (CV) Of C-max, is inversely correlated with drugs molecular weight and lipophilicity in the range of 200 < MW < 400 and 1.6 < logK(oct) < 4.3. Multiple regression analysis of C-max against physichochemical parameters demonstrated the prominent contribution of hydrogen bonding acceptability of the molecules on their maximal plasma concentration after patch administration. The findings suggest that the serum concentration profile for transdermal therapeutic systems (TTS) is a net result of the system performance, drug absorption and elimination. Thus, the variability in serum concentration is a function of variability of each process involved. This should be noted in explanation of effect of molecular features of drugs on their plasma concentration profile. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 84 条
[1]   Human skin permeation and partition: General linear free-energy relationship analyses [J].
Abraham, MH ;
Martins, F .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (06) :1508-1523
[2]   THE FACTORS THAT INFLUENCE SKIN PENETRATION OF SOLUTES [J].
ABRAHAM, MH ;
CHADHA, HS ;
MITCHELL, RC .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (01) :8-16
[3]   Pharmacokinetics of a contraceptive patch (Evra™/Ortho Evra™) containing norelgestromin and ethinyloestradiol at four application sites [J].
Abrams, LS ;
Skee, DM ;
Natarajan, J ;
Wong, FA ;
Anderson, GD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (02) :141-146
[4]   Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra™/Evra™) under conditions of heat, humidity, and exercise [J].
Abrams, LS ;
Skee, DM ;
Natarajan, J ;
Wong, FA ;
Leese, PT ;
Creasy, GW ;
Shangold, MM .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (12) :1301-1309
[5]   Pharmacokinetics and pharmacodynamics of oral testosterone enanthate plus dutasteride for 4 weeks in normal men: Implications for male hormonal contraception [J].
Amory, John K. ;
Kalhorn, Thomas F. ;
Page, Stephanie T. .
JOURNAL OF ANDROLOGY, 2008, 29 (03) :260-271
[6]   Methylphenidate transdermal system - In attention-deficit hyperactivity disorder in children [J].
Anderson, Vanessa R. ;
Scott, Lesley J. .
DRUGS, 2006, 66 (08) :1117-1126
[7]   Pharmacokinetics, metabolism, and saliva output during transidermal and extended-release oral oxybutynin administration in healthy subjects [J].
Appell, RA ;
Chancellor, MB ;
Zobrist, RH ;
Thomas, H ;
Sanders, SW .
MAYO CLINIC PROCEEDINGS, 2003, 78 (06) :696-702
[8]   Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system [J].
Auclair, B ;
Sirois, G ;
Ngoc, AH ;
Ducharme, MP .
THERAPEUTIC DRUG MONITORING, 1998, 20 (06) :607-611
[9]   Novel pharmacokinetic modelling of transdermal nitroglycerin [J].
Auclair, B ;
Sirois, G ;
Ngoc, AH ;
Ducharme, MP .
PHARMACEUTICAL RESEARCH, 1998, 15 (04) :614-619
[10]   Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): A comparison with oral selegiline capsules [J].
Azzaro, Albert J. ;
Ziemniak, John ;
Kemper, Eva ;
Campbell, Bryan J. ;
VanDenBerg, Chad .
JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (10) :1256-1267